Area of research
Rheumatology · Physiology
Research interest
Research focused on Rheumatoid arthritis and Placebo, with related work in Clinical endpoint, Cohort, Rheumatology. Notable publications include 'Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial', 'Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial', and 'Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial'.
How growing up without siblings affects the adult brain and behaviour in the CHIMGEN cohort
Pathways from early-life urbanicity to adult neurobehavioral traits via menarche timing
Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study
Risk prediction of new-onset thrombocytopenia in patients with systemic lupus erythematosus: a multicenter prospective cohort study based on Chinese SLE treatment and research group (CSTAR) registry
Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial
Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial
Management of Rheumatoid Arthritis With a Digital Health Application
A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients
Improve quality of patient care for systemic lupus erythematosus in China by enhancing the construction of Centers of Excellence
Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII
Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study
Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study
Pulmonary arterial hypertension associated with primary Sjögren's syndrome: a multicentre cohort study from China
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
VEGI Improves Outcomes in the Early Phase of Experimental Traumatic Brain Injury
Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points
Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR‐PAH study: Baseline characteristics and risk factors
Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.
PubMed 2019cited by 12position: middle
AB0430 DEVELOP A REPLICABLE MODEL FOR RATIONAL SELECTION OF STRATEGIES IN TREAT-TO-TARGET AND MAINTAIN-BEING-TARGET: REAL WORLD DATA MINING VIA SMART SYSTEM OF DISEASE MANAGEMENT (SSDM)
Advances in the diagnosis and treatment of Sjogren’s syndrome
Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial